Physician profile
Douglas E Mason
NPI 1124125562
$2,297.28
in general payments reported to CMS, 2019-2025
22 companies · $479 in 2025
The $479 reported for 2025 was more than what a typical Foot Surgery provider received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $265 · 2020: $79.43 · 2021: $163 · 2022: $315 · 2023: $649 · 2024: $348 · 2025: $479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,475.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $432.82 | 2022-2024 | Grafix Pl, Collagenase Santyl, Regranex |
| Paratek Pharmaceuticals, INC. | $300.90 | 2020-2025 | Nuzyra |
| Treace Medical Concepts, INC. | $276.39 | 2023-2024 | |
| Averitas Pharma INC. | $199.63 | 2023-2025 | Qutenza |
| Amgen INC. | $196.05 | 2025 | Krystexxa |
| Horizon Therapeutics Plc | $169.25 | 2019-2021 | |
| Bioventus LLC | $131.45 | 2023 | Exogen Ultrasound Bone Healing System |
| Nabriva Therapeutics, Plc | $81.89 | 2021 | |
| Advanced Oxygen Therapy INC. | $73.92 | 2021-2025 | Topical Oxygen Chamber For Extremities |
| Vertex Pharmaceuticals Incorporated | $65.23 | 2025 | |
| Kerecis Limited | $61.38 | 2019-2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Abbvie INC. | $51.78 | 2023 | |
| Organogenesis INC. | $49.12 | 2021-2024 | |
| Melinta Therapeutics, LLC | $39.34 | 2019 | |
| Stryker Corporation | $32.40 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $26.34 | 2022 | |
| Boston Scientific Corporation | $26.04 | 2025 | Accolade Sr |
| Merck Sharp & Dohme LLC | $23.57 | 2019 | |
| Cashflow Solutions, LLC | $19.71 | 2025 | Pcd-51 731a (US) - White, Pcd-52 737a (US) White, Lympha Press Optimal Plus(US) Bt |
| Alfasigma USA, INC. | $16.76 | 2021 | |
| Wright Medical Technology, INC. | $13.32 | 2019 | |
| Fidia Pharma USA INC. | $9.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Mason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.